FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3167149035> ?p ?o ?g. }

• W3167149035 endingPage "TPS5092" @default.
• W3167149035 startingPage "TPS5092" @default.
• W3167149035 abstract "TPS5092 Background: Prostate cancer (CaP) is the most common cancer in US men. Disseminated CaP invariably progresses to metastatic castrate-resistant prostate cancer (mCRPC). Current treatment options for mCRPC usually lead to therapeutic resistance, and novel therapies are urgently needed. PSMA is a prostate-specific antigen over-expressed on most mCRPC. Antibodies against PSMA have been used to create T-cell engaging bispecific Abs (TCEs) and chimeric antigen receptor T cells, but all such approaches to date induce frequent/severe cytokine release syndrome (CRS). We combined a high-affinity αPSMA moiety with a low-activating αCD3 binder to create TNB-585; in preclinical studies, TNB-585 showed equivalent anti-tumor efficacy but much reduced cytokine secretion compared to PSMA-targeted TCEs with a strongly activating αCD3 domain. TNB-585 also has a full length silenced Fc domain, conferring a 3-week half-life. A phase 1 study investigating the safety, pharmacokinetics (PK), anti-drug antibodies (ADA) and preliminary activity of TNB-585 in patients with mCRPC is ongoing and described. Methods: TNB585.001 (NCT04740034) is an open-label, multi-center study of TNB-585 in patients with mCRPC. The study is divided into escalation (Arm A, N=24) and expansion (Arm B, N=30) arms. Subjects who have received 2 or more prior lines of therapy are eligible. Prior exposure to PSMA-targeted therapy is permitted, as are well-controlled HBV, HCV, and HIV infection; subjects with secondary malignancies that do not interfere with the study may also be enrolled. Other key inclusion/exclusion criteria include EGFR of > 30ml/min and ECOG ≤ 2. TNB-585 is administered as an intravenous infusion every 3 weeks. Subjects must be admitted for 48 hours after their 1st dose; TNB-585 is given on an outpatient basis thereafter. Dose escalation is proceeding in Arm A via single patient cohorts until the onset of toxicity or activity; thereafter subjects enroll using a BOIN design. Arm B will start once the maximum tolerated dose (MTD) / recommended phase 2 dose (RP2D) has been selected. Subjects will be treated until progression or unacceptable toxicity. In Arm A, occurrence of dose limiting toxicities (DLTs) will drive identification of the MTD (or RP2D) based on the BOIN escalation and de-escalation boundaries (λe of 0.236 and a λd of 0.358). In Arm B accrual will be suspended if more than 33% of subjects experience a DLT event. Adverse events (AEs), laboratory profiles, and vital signs will be assessed throughout the study. AEs are graded according to the NCI CTCAE, version 5.0. The activity endpoints (per PCWG3/RECIST1.1) include overall response rate, PSA50, PSA30, CTC counts, progression free survival and overall survival. The relationship between PSMA expression (via PSMA-PET) and activity will be assessed. Clinical trial information: NCT04740034." @default.
• W3167149035 created "2021-06-22" @default.
• W3167149035 creator A5002020225 @default.
• W3167149035 creator A5002575629 @default.
• W3167149035 creator A5003463407 @default.
• W3167149035 creator A5008348981 @default.
• W3167149035 creator A5013281585 @default.
• W3167149035 creator A5035048954 @default.
• W3167149035 creator A5042356326 @default.
• W3167149035 creator A5046578250 @default.
• W3167149035 creator A5065816810 @default.
• W3167149035 creator A5072694930 @default.
• W3167149035 creator A5073142489 @default.
• W3167149035 creator A5073970384 @default.
• W3167149035 creator A5083083918 @default.
• W3167149035 date "2021-05-20" @default.
• W3167149035 modified "2023-10-16" @default.
• W3167149035 title "TNB585.001: A multicenter, phase 1, open-label, dose-escalation and expansion study of tnb-585, a bispecific T-cell engager targeting PSMA in subjects with metastatic castrate resistant prostate cancer." @default.
• W3167149035 doi "https://doi.org/10.1200/jco.2021.39.15_suppl.tps5092" @default.
• W3167149035 hasPublicationYear "2021" @default.
• W3167149035 type Work @default.
• W3167149035 sameAs 3167149035 @default.
• W3167149035 citedByCount "4" @default.
• W3167149035 countsByYear W31671490352021 @default.
• W3167149035 countsByYear W31671490352022 @default.
• W3167149035 countsByYear W31671490352023 @default.
• W3167149035 crossrefType "journal-article" @default.
• W3167149035 hasAuthorship W3167149035A5002020225 @default.
• W3167149035 hasAuthorship W3167149035A5002575629 @default.
• W3167149035 hasAuthorship W3167149035A5003463407 @default.
• W3167149035 hasAuthorship W3167149035A5008348981 @default.
• W3167149035 hasAuthorship W3167149035A5013281585 @default.
• W3167149035 hasAuthorship W3167149035A5035048954 @default.
• W3167149035 hasAuthorship W3167149035A5042356326 @default.
• W3167149035 hasAuthorship W3167149035A5046578250 @default.
• W3167149035 hasAuthorship W3167149035A5065816810 @default.
• W3167149035 hasAuthorship W3167149035A5072694930 @default.
• W3167149035 hasAuthorship W3167149035A5073142489 @default.
• W3167149035 hasAuthorship W3167149035A5073970384 @default.
• W3167149035 hasAuthorship W3167149035A5083083918 @default.
• W3167149035 hasConcept C121608353 @default.
• W3167149035 hasConcept C126322002 @default.
• W3167149035 hasConcept C143998085 @default.
• W3167149035 hasConcept C147483822 @default.
• W3167149035 hasConcept C203014093 @default.
• W3167149035 hasConcept C2777701055 @default.
• W3167149035 hasConcept C2780192828 @default.
• W3167149035 hasConcept C2780850621 @default.
• W3167149035 hasConcept C3875195 @default.
• W3167149035 hasConcept C502942594 @default.
• W3167149035 hasConcept C71924100 @default.
• W3167149035 hasConceptScore W3167149035C121608353 @default.
• W3167149035 hasConceptScore W3167149035C126322002 @default.
• W3167149035 hasConceptScore W3167149035C143998085 @default.
• W3167149035 hasConceptScore W3167149035C147483822 @default.
• W3167149035 hasConceptScore W3167149035C203014093 @default.
• W3167149035 hasConceptScore W3167149035C2777701055 @default.
• W3167149035 hasConceptScore W3167149035C2780192828 @default.
• W3167149035 hasConceptScore W3167149035C2780850621 @default.
• W3167149035 hasConceptScore W3167149035C3875195 @default.
• W3167149035 hasConceptScore W3167149035C502942594 @default.
• W3167149035 hasConceptScore W3167149035C71924100 @default.
• W3167149035 hasIssue "15_suppl" @default.
• W3167149035 hasLocation W31671490351 @default.
• W3167149035 hasOpenAccess W3167149035 @default.
• W3167149035 hasPrimaryLocation W31671490351 @default.
• W3167149035 hasRelatedWork W1967568184 @default.
• W3167149035 hasRelatedWork W1974496092 @default.
• W3167149035 hasRelatedWork W2031697966 @default.
• W3167149035 hasRelatedWork W2340195356 @default.
• W3167149035 hasRelatedWork W2528840586 @default.
• W3167149035 hasRelatedWork W2762580124 @default.
• W3167149035 hasRelatedWork W2809002819 @default.
• W3167149035 hasRelatedWork W4243514755 @default.
• W3167149035 hasRelatedWork W4282916079 @default.
• W3167149035 hasRelatedWork W4308769187 @default.
• W3167149035 hasVolume "39" @default.
• W3167149035 isParatext "false" @default.
• W3167149035 isRetracted "false" @default.
• W3167149035 magId "3167149035" @default.
• W3167149035 workType "article" @default.